Key result
Antisense oligonucleotides and small-interfering RNA therapies targeting APOC3 and ANGPTL3 show significant potential in reducing triglyceride levels and acute pancreatitis risk in familial chylomicronemia syndrome.
Why the study?
Familial chylomicronemia syndrome is a rare disorder affecting triglyceride metabolism requiring discussion of new treatment approaches targeting APOC3 and ANGPTL3.
Emerging ASO and siRNA therapies targeting APOC3 and ANGPTL3 offer promising new treatment avenues for familial chylomicronemia syndrome with potentially improved safety profiles.
May support ASO/siRNA use in rare TG disorders despite limits; leaves open long-term safety and access.
PURPOSE OF REVIEW: This review discusses new treatment approaches for familial chylomicronemia syndrome (FCS), a rare disorder affecting triglyceride metabolism. The focus is on antisense oligonucleotides (ASO) and small-interfering RNA (siRNA) therapies targeting APOC3 and angiopoietin-like protein 3 (ANGPTL3). RECENT FINDINGS: Volanesorsen, an ASO targeting APOC3, has shown effectiveness in managing FCS, multifactorial chylomicronemia, and familial partial lipodystrophy, but its use is limited by thrombocytopenia. Emerging therapies, Olezarsen (ASO anti-APOC3) and Plozasiran (siRNA anti-APOC3), both conjugated with GalNAc, show promise in reducing acute pancreatitis risk without platelet concerns. ANGPTL3 inhibition requires residual lipoprotein lipase (LPL) activity, with only siRNA-based therapies-zodasiran and solbinsiran-under investigation. Suppressing APOC3 expression and targeting ANGPTL3 via siRNA offer significant potential, but long-term studies are needed to confirm their efficacy and safety. Future research may explore gene-editing strategies using lipid nanoparticle-based CRISPR-Cas9 delivery for more durable treatment outcomes.
No takes yet. Share an insight, caveat, or question.
Izar et al. (2025) conducted a review in Familial Chylomicronemia Syndrome (FCS) and severe hypertriglyceridemia. Antisense oligonucleotides (ASO) and small-interfering RNA (siRNA) targeting APOC3 and ANGPTL3 was evaluated. Antisense oligonucleotides and small-interfering RNA therapies targeting APOC3 and ANGPTL3 show significant potential in reducing triglyceride levels and acute pancreatitis risk in familial chylomicronemia syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: